narlaprevir

Narlaprevir is an oral small molecule antiviral drug that acts as a potent and selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. By reversibly binding to the active site of the NS3 protease via its ketoamide functional group, narlaprevir blocks viral polyprotein processing, thereby inhibiting HCV replication in infected host cells. It is primarily indicated for the treatment of chronic hepatitis C virus infection genotype 1, used in combination with ritonavir, pegylated interferon alfa, and ribavirin in adults with compensated liver disease who are either treatment-naïve or have failed previous dual therapy. Narlaprevir was originally developed by Schering-Plough and later further developed by R-Pharm; it is marketed under the brand name Arlansa in Russia[1][2][5][7].

Brand names

Arlansa

Other names

865466-24-6